logo
Share SHARE
FONT-SIZE Plus   Neg

Medtronic Says FDA OKs Expanded Indication For Cardiac Resynchronization Therapy

Medtronic, Inc. (MDT) said that the FDA approved an expanded indication for its cardiac resynchronization therapy with implantable cardioverter defibrillator, or CRT-D, devices. The expanded indication includes New York Heart Association Class II heart failure patients with a left ventricular ejection fraction of less than or equal to 30 percent, left bundle branch block, and a QRS duration greater than or equal to 130 milliseconds.

The company specified that the FDA's decision for the expanded indication rests on data from the pivotal REVERSE and landmark RAFT clinical trials, which demonstrated that CRT-D can benefit mildly symptomatic heart failure patients by reducing mortality and heart failure hospitalization rates.

With today's approval, the advanced therapy can now be used earlier, in a mildly symptomatic heart failure patient population, potentially improving survival, reducing hospitalizations, and preventing disease progression.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Media and entertainment giant Walt Disney Co. said Tuesday that Christine McCarthy, the company's Treasurer for the past 15 years, will succeed James Rasulo as Chief Financial Officer. A blast at the Al-Imam al-Sadeq mosque in Kuwaiti capital killed eight people. Several people were wounded in the explosion, probably a suicide bombing, after the Friday prayers. Many are said to be in critical condition. One was killed in a probable ISIS attack at U.S. based Air products and Chemicals' industrial site in France. According to media reports, a car disguised as a delivery vehicle was rammed into Air product site in Schiltigheim, Southeast France. Police arrested a young man of around 30 years old, who is suspected to have connections with Islamic State.
comments powered by Disqus
RELATED NEWS
Trade MDT now with 
Follow RTT